Test-retest reliability of a quantitative bone SPECT/CT

Test-retest reliability of a quantitative bone SPECT/CT - Test-retest reliability of a quantitative bone SPECT/CT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028645

Enrollment

Registered

2017-09-01

Start date

2017-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Bone scintigraphy and SPECT/CT

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: #1 Written informed consent was acquired #2 Twenty years or older #3 Prostate cancer was diagnosed or suspected #4 Bone scintigraphy was performed or planned #5 Second bone scintigraphy can be performed in 4-10 days after the first bone scan numbered #4

Exclusion criteria

Exclusion criteria: #1 Unable to keep supine position for 1 hour #2 Anti-cancer drug, hormone drug, radionuclide treatment or radiation therapy for bone lesion was planned during 2 bone scans #3 Person in charge considered inappropriate to include to this study

Design outcomes

Primary

Measure	Time frame
test-retest reliability	—

Countries

Japan

Contacts

Public ContactYamane Tomohiko

Saitama Medical University International Medical Center Nuclear Medicine

yamane_t@saitama-med.ac.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026